



16 August 2024



PolyNovo Limited ABN 96 083 866 862

2/320 Lorimer Street Port Melbourne VIC Australia 3207

P +61 (0) 3 8681 4050 F +61 (0) 3 8681 4099

# ASX Announcement

# FY24 Results Presentation

The Company's FY24 results presentation will be live streamed on Friday 23 August at 2.00pm AEST.

To access the webcast, shareholders will need to register at the following website prior to the presentation:

## Early Registration | PolyNovo - FY24 Results (choruscall.com)

Shareholders who would like to ask a question are asked to email their question to investor@polynovo.com in advance of the event and we will endeavor to answer your question prior to or during the webcast.

Alternatively, shareholders can ask questions during the live webcast by submitting their questions via the webcast platform.

Broker analysts who cover the company can ask questions live.

This announcement has been authorised by PolyNovo General Counsel & Company Secretary, Lior Harel.

### **About PolyNovo®**

PolyNovo is a disruptive ASX 200 medical technology company, based out of Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 50,000+ patients across 41 countries, the company is investing for growth via new products, indications, and markets with a view to treat millions more. For more information see polynovo.com

### About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.